Thymidine enhancement of methotrexate and 5-fluorouracil toxicity in cultured human colon carcinoma.

abstract：PURPOSE:We conducted a phase II study of combination chemotherapy with nedaplatin (NP) and irinotecan (CPT) followed by gefitinib to determine the effects and toxicities in patients 70 years or older with unresectable non-small cell lung cancer (NSCLC). METHODS:Eligible patients were entered to receive 3 courses of 50...

journal_title：Cancer chemotherapy and pharmacology

authors： Oshita F,Yamada K,Saito H,Noda K

更新日期：2008-08-01 00:00:00

abstract：PURPOSE:In clinical trials, the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) administered concomitantly with first-line cytotoxicity chemotherapy failed to confer a survival benefit to patients with non-small-cell lung cancer (NSCLC). The aim of this study was to test whether paclitaxel followe...

journal_title：Cancer chemotherapy and pharmacology

authors： Cheng H,An SJ,Zhang XC,Dong S,Zhang YF,Chen ZH,Chen HJ,Guo AL,Lin QX,Wu YL

更新日期：2011-03-01 00:00:00

abstract：PURPOSE:Fruquintinib (HMPL-013) is a novel, potent, and highly selective tyrosine kinase inhibitor targeting the vascular endothelial growth factor receptors (1, 2 and 3). This study was conducted to investigate the metabolism, excretion, and pharmacokinetics of HMPL-013 after a single oral dose to healthy Chinese men....

journal_title：Cancer chemotherapy and pharmacology

authors： Zhou S,Shao F,Xu Z,Wang L,Jin K,Xie L,Chen J,Liu Y,Zhang H,Ou N

更新日期：2017-09-01 00:00:00

abstract：:The chemotherapeutic effects of all-trans-retinoic acid (atRA) are mediated by the retinoic acid receptor beta (RARbeta), but RARbeta expression is reduced in a number of head and neck carcinoma (HNSCC) cells which causes resistance to RA treatment in half the patients with HNSCC. The possible mechanism for the reduce...

journal_title：Cancer chemotherapy and pharmacology

authors： Whang YM,Choi EJ,Seo JH,Kim JS,Yoo YD,Kim YH

更新日期：2005-11-01 00:00:00

abstract：:In January 1983, the German Society of Pediatric Oncology started a cooperative trial (MAKEI 83) for non-testicular germ-cell tumors. The pilot phase closed in December 1985. The treatment regimen was stratified according to histology, tumor site and tumor stage. In malignant non-seminomatous germ-cell tumors (mNSGCTs...

journal_title：Cancer chemotherapy and pharmacology

authors： Gobel U,Calaminus G,Häas RJ,Jurgens H,Niethammer D,Ritter J,Spaar HJ,Harms D

更新日期：1989-01-01 00:00:00

abstract：:We established an etoposide (VP-16)-resistant human small-cell lung cancer cell line (H69/VP) by stepwise exposure to VP-16. The resistance of H69/VP to VP-16 was 9.4-fold that of the parent cell line (H69/P). H69/VP showed cross-resistance to Adriamycin (ADM), (4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidinopiperidino) c...

journal_title：Cancer chemotherapy and pharmacology

authors： Minato K,Kanzawa F,Nishio K,Nakagawa K,Fujiwara Y,Saijo N

更新日期：1990-01-01 00:00:00

abstract：PURPOSE:The aim of this study is to examine the factors affecting sensitivity to cisplatin, carboplatin, and oxaliplatin in human colorectal tumor cell lines. METHODS:Caco-2, DLD-1, HCT-15, HCT116, LS180, SW620, and WiDr cells were used. Their growth inhibition by platinum derivatives was evaluated with a WST-1 assay ...

journal_title：Cancer chemotherapy and pharmacology

authors： Kitada N,Takara K,Minegaki T,Itoh C,Tsujimoto M,Sakaeda T,Yokoyama T

更新日期：2008-09-01 00:00:00

abstract：PURPOSE:The aim of the study was to assess the clinical activity and toxicity of oxaliplatin and leucovorin in combination with bolus and continuous infusional 5-fluorouracil administered every 2 weeks (modified FOLFOX-6 regimen) to patients with adenocarcinoma of an unknown primary site (ACUP). METHODS:Previously unt...

journal_title：Cancer chemotherapy and pharmacology

authors： Shin DY,Choi YH,Lee HR,Na II,Yuh YJ,Kim BS,Chung IJ,Bae WK,Shim HJ,Song EK,Yang SH,Kang HJ

更新日期：2016-01-01 00:00:00

abstract：UNLABELLED:Oxaliplatin (OPT), a third-generation platinating agent, is currently being evaluated in a phase II clinical trial in head and neck cancer patients and in a phase I clinical trial in combination with paclitaxel (TXL). PURPOSE:The aim of this study was to investigate the pharmacokinetics and biological corre...

journal_title：Cancer chemotherapy and pharmacology

authors： Liu J,Kraut E,Bender J,Brooks R,Balcerzak S,Grever M,Stanley H,D'Ambrosio S,Gibson-D'Ambrosio R,Chan KK

更新日期：2002-05-01 00:00:00

abstract：PURPOSE:ABT-888 inhibits poly(ADP-ribose) polymerase (PARP) and may enhance the efficacy of chemotherapy and radiation in CNS tumors. We studied the plasma and cerebrospinal fluid (CSF) pharmacokinetics (PK) of ABT-888 in a non-human primate (NHP) model that is highly predictive of human CSF penetration. METHODS:ABT-8...

journal_title：Cancer chemotherapy and pharmacology

authors： Muscal JA,Thompson PA,Giranda VL,Dayton BD,Bauch J,Horton T,McGuffey L,Nuchtern JG,Dauser RC,Gibson BW,Blaney SM,Su JM

更新日期：2010-02-01 00:00:00

abstract：PURPOSE:We reported the first case of phenytoin intoxication due to the concomitant use of phenytoin and TS-1, together with a review of the literature regarding the occurrence of phenytoin intoxication due to the concomitant use of phenytoin and fluoropyrimidine antitumor drugs such as fluorouracil (5-FU) and tegafur ...

journal_title：Cancer chemotherapy and pharmacology

authors： Tsuda A,Fujiyama J,Miki A,Hori S,Ohtani H,Sawada Y

更新日期：2008-08-01 00:00:00

abstract：PURPOSE:Although irinotecan monotherapy is often used in third-line treatment after the failure of taxanes in Japanese clinical practice, its survival benefit is still unclear. The aim of this study is to investigate the efficacy and safety of irinotecan monotherapy as third-line treatment. METHODS:Clinical data from ...

journal_title：Cancer chemotherapy and pharmacology

authors： Kawakami T,Machida N,Yasui H,Kawahira M,Kawai S,Kito Y,Yoshida Y,Hamauchi S,Tsushima T,Todaka A,Yokota T,Yamazaki K,Fukutomi A,Onozawa Y

更新日期：2016-10-01 00:00:00

abstract：PURPOSE:A metronomic schedule of chemotherapy (resulting in a greater frequency of drug delivery) has shown efficacy in head and neck cancer. Our aim was to investigate the overall survival in tongue cancer patients with metronomic neoadjuvant chemotherapy with bleomycin compared to those with surgery alone. METHODS:I...

journal_title：Cancer chemotherapy and pharmacology

authors： Kina S,Nakasone T,Kinjo T,Maruyama T,Kawano T,Arasaki A

更新日期：2016-10-01 00:00:00

abstract：PURPOSE:The present study was designed to determine pharmacological and biochemical properties of 2-methoxyantimycin A analogs (OMe-A1, OMe-A2, OMe-A3, and OMe-A5), which are novel antitumor compounds, and provide a basis for future pharmaceutical development, preclinical evaluation, and clinical trials. METHODS:A hig...

journal_title：Cancer chemotherapy and pharmacology

authors： Wang H,Li M,Rhie JK,Hockenbery DM,Covey JM,Zhang R,Hill DL

更新日期：2005-09-01 00:00:00

abstract：BACKGROUND:No specific treatment guidelines are available for triple-negative breast cancers, defined by a lack of expression of estrogen (ER), progesterone (PgR), and HER2 receptors. PATIENTS AND METHODS:We investigated in patients with T2-T3 N0-3 ER, PgR <10% and HER2 negative breast cancers the activity both in ter...

journal_title：Cancer chemotherapy and pharmacology

authors： Torrisi R,Balduzzi A,Ghisini R,Rocca A,Bottiglieri L,Giovanardi F,Veronesi P,Luini A,Orlando L,Viale G,Goldhirsch A,Colleoni M

更新日期：2008-09-01 00:00:00

abstract：:Hydroxyurea has been used for decades and it is still valuable for the treatment of some types of cancer. It inhibits ribonucleotide reductase (RNR) enzyme known to be crucial in the conversion of ribonucleotides into deoxyribonucleotides. However, nowadays the main focus has shifted to structurally similar hydroxamic...

journal_title：Cancer chemotherapy and pharmacology

authors： Saban N,Bujak M

更新日期：2009-07-01 00:00:00

abstract：:The toxicity of single doses of the anthracycline epirubicin was compared in the rat after either the intravenous (i.v.; 2-6 mg/kg) or intraperitoneal (i.p.; 4-8 mg/kg) administration of the drug. These doses produced comparable acute toxicity that was characterised by a dose-dependent, transient reduction in body wei...

journal_title：Cancer chemotherapy and pharmacology

authors： Yeung TK,Simmonds RH,Hopewell JW

更新日期：1989-01-01 00:00:00

abstract：PURPOSE:A standard chemotherapy regimen for neuroendocrine carcinoma of the gastrointestinal tract (GI-NEC) has not been established. Treatment usually consists of platinum doublets, consistent with the standard treatment for small-cell lung cancer (SCLC), with which it shares clinicopathological similarities. Here, we...

journal_title：Cancer chemotherapy and pharmacology

authors： Asayama M,Fuse N,Yoshino T,Yano T,Tahara M,Doi T,Fujii S,Ohtsu A

更新日期：2011-11-01 00:00:00

abstract：PURPOSE:To review the 20 years of experience at M. D. Anderson Cancer Center with a combined-modality approach against inflammatory breast carcinoma. PATIENTS AND METHODS:A total of 178 patients with inflammatory breast carcinoma were treated in the past 20 years at M. D. Anderson Cancer Center by a combined-modality ...

journal_title：Cancer chemotherapy and pharmacology

authors： Ueno NT,Buzdar AU,Singletary SE,Ames FC,McNeese MD,Holmes FA,Theriault RL,Strom EA,Wasaff BJ,Asmar L,Frye D,Hortobagyi GN

更新日期：1997-01-01 00:00:00

abstract：:A three-compartment model was fitted to idarubicin data in a NONMEM pooled-data approach. Clearance (CL) of 221.7 ml/min was relatively high, and drug distribution was rapid (CLD = 248.3 ml/min) and extensive [steady-state volume of distribution (Vss) 24 1]. The area under the concentration-time curve (AUC) of idarbic...

journal_title：Cancer chemotherapy and pharmacology

authors： Looby M,Linke R,Weiss M

更新日期：1997-01-01 00:00:00

abstract：:In five cancer patients we have determined the pharmacokinetics of 4'-deoxydoxorubicin (4'-DOX), its alcoholic metabolite 4'-deoxydoxorubicinol and the occurrence of circulating 7-deoxyaglycone metabolites. The 7-deoxyaglycone of the alcohol metabolite, the major aglycone of Adriamycin (ADR) present in man, was not de...

journal_title：Cancer chemotherapy and pharmacology

authors： Cummings J,Kerr DJ,Kaye SB

更新日期：1987-01-01 00:00:00

abstract：PURPOSE:We evaluated the efficacy and safety of capecitabine and temozolomide (CAPTEM) in patients with metastatic neuroendocrine tumors (NETs) to the liver. This regimen was based on our studies with carcinoid cell lines that showed synergistic cytotoxicity with sequence-specific dosing of 5-fluorouracil preceding tem...

journal_title：Cancer chemotherapy and pharmacology

authors： Fine RL,Gulati AP,Krantz BA,Moss RA,Schreibman S,Tsushima DA,Mowatt KB,Dinnen RD,Mao Y,Stevens PD,Schrope B,Allendorf J,Lee JA,Sherman WH,Chabot JA

更新日期：2013-03-01 00:00:00

abstract：:Our previous randomised trial in patients with advanced ovarian cancer indicated a significant response and survival advantage for those receiving high-dose (100 mg/m2) as compared with low-dose (50 mg/m2) cisplatin in combination with cyclophosphamide (750 mg/m2). However, this was accompanied by more toxicity; perip...

journal_title：Cancer chemotherapy and pharmacology

authors： Cassidy J,Paul J,Soukop M,Habeshaw T,Reed NS,Parkin D,Kaye SB

更新日期：1998-01-01 00:00:00

abstract：PURPOSE:In vitro and in vivo preclinical models have demonstrated synergistic activity when topoisomerase I and II inhibitors are administered sequentially. Topoisomerase I inhibitors increase topoisomerase II levels and increase cell kill induced by topoisomerase II poisons. We evaluated this hypothesis in a cohort of...

journal_title：Cancer chemotherapy and pharmacology

authors： Dowlati A,Levitan N,Gordon NH,Hoppel CL,Gosky DM,Remick SC,Ingalls ST,Berger SJ,Berger NA

更新日期：2001-01-01 00:00:00

abstract：:A 62-year-old patient on long-term haemodialysis who developed an inoperable T2N3Mo squamous-cell carcinoma of the larynx was treated with weekly low-dose methotrexate (MTX) after failing to respond to radiotherapy. The patient was initially given one dose of 10 mg MTX (6 mg/m2) as a 1-h infusion, then he received thr...

journal_title：Cancer chemotherapy and pharmacology

authors： Thomson AH,Daly M,Knepil J,Harden P,Symonds P

更新日期：1996-01-01 00:00:00

abstract：:Increasing the expression of human multidrug resistance (MDR) 1 gene in bone marrow cells to prevent or circumvent bone morrow toxicity from chemotherapy agent is a high priority of dose intensification protocols. In this study, we have used a tumor-bearing model to investigate the chemoprotection effect of MDR1 gene ...

journal_title：Cancer chemotherapy and pharmacology

authors： Guo CB,Li YC,Jin XQ

更新日期：2006-07-01 00:00:00

abstract：:Exposure of cells of the K-562 erythroleukemia cell line to 4-hydroperoxycyclophosphamide (4-HC), an analog of activated cyclophosphamide, causes a concentration-dependent inhibition of in vitro colony formation by these cells. For investigation of the role of glutathione (GSH) in the metabolism of 4-HC, GSH levels of...

journal_title：Cancer chemotherapy and pharmacology

authors： Peters RH,Ballard K,Oatis JE,Jollow DJ,Stuart RK

更新日期：1990-01-01 00:00:00

abstract：:Methylene blue (MB) is a phenothiazine with radio and photosensitizing properties and anti-tumoral activity. Our group has shown that MB was capable of inhibiting the in vitro growth of erythroleukemic cells with multidrug resistance (MDR). However, there are no studies comparing the cytotoxicity of this molecule for ...

journal_title：Cancer chemotherapy and pharmacology

authors： Kirszberg C,Rumjanek VM,Capella MA

更新日期：2005-12-01 00:00:00

abstract：:Dianhydrogalactitol (DAG) increased the life span of both BCNU-sensitive and -resistant L1210 tumor-bearing mice. However, the BCNU-resistant strain showed slightly lower sensitivity against DAG, which could be overcome by an increase in drug dose of ca. 20%. The somewhat lower sensitivity was proportional to a slight...

journal_title：Cancer chemotherapy and pharmacology

authors： Institóris E,Szikla K,Otvös L,Gál F

更新日期：1989-01-01 00:00:00

abstract：:Long-term results were analyzed in terms of tumor progression and survival in patients with superficial bladder cancer who were enrolled in the second intravesical chemoprophylactic study of the Japanese Urological Cancer Research Group for Adriamycin, which was started in July 1982. This study was a prospective, rand...

journal_title：Cancer chemotherapy and pharmacology

authors： Akaza H,Koiso K,Kotake T,Matsumura Y,Isaka S,Machida T,Obata K,Ohashi Y,Ohe H,Ohi Y

更新日期：1992-01-01 00:00:00